ANTIRETROVIRAL DRUG LEVELS AND INTERACTIONS AFFECT LIPID, LIPOPROTEIN, AND

抗逆转录病毒药物水平和相互作用影响脂质、脂蛋白和

• 批准号: 7953989
• 负责人: Susan L. Rosenkranz
• 金额: $ 0.72万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-02-01 至 2010-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7953989
• 关键词: Adult; Affect; Amprenavir; Anti-Retroviral Agents; C-Peptide; Computer Retrieval of Information on Scientific Projects Database; Drug Kinetics; Enrollment; Fasting; Funding; Glucose; Grant; High Density Lipoprotein Cholesterol; Indinavir; Institution; Insulin; Lipids; Lipoprotein (a); Mass Spectrum Analysis; Measures; Metabolic; Metabolic syndrome; Methods; Modeling; Nelfinavir; Patients; Pharmaceutical Preparations; Protease Inhibitor; Randomized; Research; Research Personnel; Resources; Ritonavir; Saquinavir; Source; Triglycerides; United States National Institutes of Health; biomedical resource; efavirenz; glucose metabolism; non-nucleoside reverse transcriptase inhibitors; open label

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Background: HIV-infected patients treated with antiretroviral medications (ARVs) develop undesirable changes in lipid and glucose metabolism that mimic the metabolic syndrome and may be proatherogenic. Antiretroviral drug levels and their interactions may contribute to these metabolic alterations. Methods: Fifty six HIV-seronegative adults were enrolled in an open-label, randomized, pharmacokinetic interaction study, and received a nonnucleoside reverse transcriptase inhibitor (efavirenz on days 1-21) plus a protease inhibitor (PI; amprenavir on days 11-21), with a second PI on days 15-21 (saquinavir, nelfinavir, indinavir, or ritonavir). Fasting triglycerides, total LDL-and HDL-cholesterol, glucose, insulin, and C-peptide levels were measured on days 0, 14, 21, and 2-3 weeks after discontinuing drugs. Regression models were used to estimate changes in these parameters and associations between these changes and circulating levels of study drugs.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 中心，不一定是研究者的机构。 背景：接受抗逆转录病毒药物（ARV）治疗的 HIV 感染患者会出现类似于代谢综合征的不良脂质和葡萄糖代谢变化，并可能导致动脉粥样硬化。抗逆转录病毒药物水平及其相互作用可能导致这些代谢改变。方法：56 名 HIV 血清阴性成人参加了一项开放标签、随机、药代动力学相互作用研究，并接受非核苷类逆转录酶抑制剂（第 1-21 天的依非韦伦）加蛋白酶抑制剂（PI；第 11-21 天的安普那韦） ），在第 15-21 天进行第二次 PI（沙奎那韦、奈非那韦、茚地那韦或利托那韦）。在停药后第 0、14、21 和 2-3 周测量空腹甘油三酯、总 LDL 和 HDL 胆固醇、葡萄糖、胰岛素和 C 肽水平。使用回归模型来估计这些参数的变化以及这些变化与研究药物的循环水平之间的关联。